Pliant Therapeutics, Inc.

NasdaqGS:PLRX 株式レポート

時価総額：US$72.4m

Pliant Therapeutics マネジメント

マネジメント 基準チェック /34

現在、CEO に関する十分な情報がありません。

主要情報

Bernard Coulie

最高経営責任者

US$5.5m

報酬総額

CEO給与比率12.48%
CEO在任期間10.6yrs
CEOの所有権1.2%
経営陣の平均在職期間3.7yrs
取締役会の平均在任期間3.5yrs

経営陣の近況

Recent updates

分析記事 • Aug 19

Here's Why We're Watching Pliant Therapeutics' (NASDAQ:PLRX) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Seeking Alpha • Feb 24

Pliant Therapeutics: A Reverse Arbitrage Opportunity Driven By A Poison Pill Expiration

Summary Pliant Therapeutics trades at a deep discount to net cash after Bexotegrast's Phase 3 failure, with a $70M market cap versus $186M cash. Activist Kevin Tang holds 9.6%; given the 85%+ institutional base, the March 2026 poison pill expiration signals a potential liquidation or premium buyout. PLRX's cash burn has been slashed, extending runway to 2028, but continued independent operation is untenable; forced liquidation or cash privatization is highly likely in my opinion. I exploit negative EV and high implied volatility by selling cash-secured $1.00 puts expiring July 2026, targeting a >50% annualized return with limited downside. Read the full article on Seeking Alpha
Seeking Alpha • Feb 11

Pliant Therapeutics: Strange Volatility

Summary Pliant Therapeutics paused its phase 2b/3 trial of bexotegrast for idiopathic pulmonary fibrosis due to DSMB recommendations, causing significant stock volatility. High trading volumes and sharp stock declines occurred before the announcement, indicating potential insider activity, making PLRX highly risky for retail investors. The DSMB's rationale for pausing the trial remains unclear, with no major safety issues previously reported, adding to the uncertainty. PLRX has a cash runway of 5–6 quarters, but faces risks due to volatile stock movements and confusing trial data; I recommend avoiding PLRX. Read the full article on Seeking Alpha
分析記事 • Jan 02

Pliant Therapeutics (NASDAQ:PLRX) Has Debt But No Earnings; Should You Worry?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
分析記事 • Sep 13

Is Pliant Therapeutics (NASDAQ:PLRX) Using Too Much Debt?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...
Seeking Alpha • Sep 11

Pliant Therapeutics: Good Data, But Will Need Watching

Summary Pliant Therapeutics' stock initially surged, but has since fallen due to mixed trial results and competitive pressures. Bexotegrast showed promising results in IPF and PSC trials, but dose-response inconsistencies and competition raise concerns. Despite positive data, the stock's decline suggests market skepticism, further exacerbated by Novartis ending a partnership. With a cash runway of 5-6 quarters, PLRX needs clarity on regulatory plans and later-stage trial data before making investment decisions. Read the full article on Seeking Alpha
分析記事 • Jun 07

Should Shareholders Reconsider Pliant Therapeutics, Inc.'s (NASDAQ:PLRX) CEO Compensation Package?

Key Insights Pliant Therapeutics' Annual General Meeting to take place on 13th of June CEO Bernard Coulie's total...
分析記事 • Feb 27

Is Pliant Therapeutics (NASDAQ:PLRX) Weighed On By Its Debt Load?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
分析記事 • Jul 21

Is Pliant Therapeutics (NASDAQ:PLRX) Using Debt Sensibly?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
分析記事 • Mar 13

Health Check: How Prudently Does Pliant Therapeutics (NASDAQ:PLRX) Use Debt?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
分析記事 • Sep 10

Is Pliant Therapeutics (NASDAQ:PLRX) Weighed On By Its Debt Load?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
Seeking Alpha • Aug 20

Pliant Therapeutics: Wait For A Better Price To Get In

PLRX went up 200% on strong phase 2a data in IPF. Even a subsequent large dilution was unable to dampen enthusiasm. A better, more derisked price after next year's 320mg data drop will be a good time to buy in. I wrote about a small company named Pliant Therapeutics (PLRX) two years ago. Pliant interested me because despite being an under-the-radar company, it had important collaborations, and it worked in fibrotic diseases. In July, Pliant stock went up after data from a phase 2a trial - designed to test safety and tolerability - also showed the drug’s efficacy in improving forced vital capacity or FVC in idiopathic pulmonary fibrosis patients. Although a trial of only 12 weeks may not be enough to convince scientists, and while there was confusion about dose dependent improvements because a smaller dose showed better efficacy than a higher one, Pliant stock has been on the rise. Data from a higher dosage cohort, coming next year, will help remove the confusion. Interestingly, Pliant’s own CEO once doubted that such a small trial will show FVC improvements. Pliant works in integrin-mediated inhibition of the TGF-β pathway, which reduces fibrosis and is safe. The science is described thus in the 10-K: We believe that tissue-specific inhibition of TGF-β may hold the key to successfully treating fibrosis. In normal tissues, TGF-β is activated in response to tissue injury which initiates a cascade that results in collagen production and, ultimately, scar formation to heal the tissue. In fibrosis, however, TGF-β signaling becomes dysregulated, with TGF-β being continuously activated, leading to excess collagen deposition, even in the absence of acute tissue injury. TGF-β, while implicated in fibrosis pathophysiology, is expressed, and intermittently activated across all tissue types and plays important, contextspecific roles in tissue homeostasis. Therefore, TGF-β cannot be blocked systemically without disrupting these homeostatic functions and causing significant toxicities. To treat fibrosis more precisely in specific tissues, we believe it is crucial to discover and treat the underlying mechanism causing excess TGF-β activation. Our scientific founders are pioneers in elucidating the role of specific extracellular receptors known as integrins as a key element in the activation of TGF-β. The company is running trials in Idiopathic Pulmonary Fibrosis or IPF and Primary Sclerosing Cholangitis or PSC. The product candidate is called PLN-74809. These are ongoing phase 2a trials with data to topline next year. Another candidate, PLN-1474, is being developed for NASH-Associated Liver Fibrosis in collaboration with Novartis (NVS). This year, the company announced data from a proof of concept trial. From the 10-K: In February 2022, we announced positive results from an expanded PLN-74809 Phase 1b proof-of-mechanism trial. This study evaluated PLN74809's ability to suppress TGF-β activation in the lungs of healthy volunteers as measured through relative pSmad2 levels in alveolar macrophages collected through bronchioalveolar lavage ((BAL)) at 6 hours and 24 hours after the last dose. The trial was conducted in two parts. Part 1 evaluated PLN-74809 at doses of 80 mg and 160 mg versus placebo and Part 2 evaluated PLN-74809 at 320 mg versus placebo. PLN-74809 demonstrated clear evidence of on-target biological activity in the lungs of healthy participants. Results showed that PLN-74809 inhibited TGF-β activation by up to 92% and 76% at 6- and 24-hours, respectively, following dosing. PLN-74809 was well tolerated with mostly mild adverse events, and no severe adverse events. There was no dose relationship associated with adverse events, no serious adverse events (SAEs) and no treatment discontinuations due to adverse events. This trial further defines the relationship between plasma exposure of PLN-74809 and TGF-β inhibition in the lung and will guide dose selection in future trials.
Seeking Alpha • Aug 08

Pliant Therapeutics GAAP EPS of -$0.82 misses by $0.01, revenue of $4.99M

Pliant Therapeutics press release (NASDAQ:PLRX): Q2 GAAP EPS of -$0.82 misses by $0.01. Revenue of $4.99M (+178.8% Y/Y).
分析記事 • Jul 28

Is Pliant Therapeutics (NASDAQ:PLRX) In A Good Position To Deliver On Growth Plans?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Jul 21

Pliant's PLN-74809 gets FDA fast track status for liver disease

The U.S. Food and Drug Administration (FDA) granted fast track designation to Pliant Therapeutics' (NASDAQ:PLRX) PLN-74809 to treat primary sclerosing cholangitis (PSC). PSC is a chronic liver disease in which the bile ducts — which carry the digestive fluid from the liver to the small intestine — become inflamed and scarred causing them to become hard and narrow leading to liver damage. People with PSC may also also have inflammatory bowel disease. The company said PLN-74809 is currently being tested as part of a phase 2a trial called  INTEGRIS-PSC, data from which is expected in H1 2023. PLRX +2.44% to $20.17 premarket July 21
Seeking Alpha • Jul 11

Pliant climbs 48% as mid-stage trial for lung disease therapy meets key goals

The shares of clinical-stage biopharma Pliant Therapeutics (NASDAQ:PLRX) gained ~48% in the pre-market Monday after the company announced its mid-stage trial for PLN-74809 in idiopathic pulmonary fibrosis (IPF) reached key goals. The 90-patient Phase 2a multinational study met its primary and secondary endpoints indicating that the study drug was well tolerated over 12 weeks of treatment with a favorable pharmacokinetic profile, the company said. According to data, PLN-74809 demonstrated dose-dependent effects on forced vital capacity (FVC) and Quantitative Lung Fibrosis (QLF) imaging compared to placebo over 12 weeks. The drug was found to be safe across all three doses of 40 mg, 80 mg, and 160 mg, with 97% in the 67-patient active arm completing the treatment with no discontinuations due to adverse events, according to Pliant (PLRX). In the near-term, the company plans to submit the data to regulators targeting the late-stage development of PLN-74809. According to Seeking Alpha contributor Terry Chrisomalis, a major catalyst awaits Pliant (PLRX) investors in early next year.

CEO報酬分析

Pliant Therapeutics の収益と比較して、Bernard Coulie の報酬はどのように変化したか？
日付総報酬給与会社業績
Jun 30 2026n/an/a

-US$92m

Mar 31 2026n/an/a

-US$113m

Dec 31 2025US$5mUS$682k

-US$149m

Sep 30 2025n/an/a

-US$175m

Jun 30 2025n/an/a

-US$207m

Mar 31 2025n/an/a

-US$220m

Dec 31 2024US$7mUS$641k

-US$210m

Sep 30 2024n/an/a

-US$202m

Jun 30 2024n/an/a

-US$185m

Mar 31 2024n/an/a

-US$171m

Dec 31 2023US$11mUS$610k

-US$161m

Sep 30 2023n/an/a

-US$155m

Jun 30 2023n/an/a

-US$144m

Mar 31 2023n/an/a

-US$133m

Dec 31 2022US$11mUS$587k

-US$123m

Sep 30 2022n/an/a

-US$113m

Jun 30 2022n/an/a

-US$109m

Mar 31 2022n/an/a

-US$103m

Dec 31 2021US$5mUS$556k

-US$97m

Sep 30 2021n/an/a

-US$92m

Jun 30 2021n/an/a

-US$81m

Mar 31 2021n/an/a

-US$75m

Dec 31 2020US$2mUS$499k

-US$42m

Sep 30 2020n/an/a

US$18m

Jun 30 2020n/an/a

US$19m

Mar 31 2020n/an/a

US$20m

Dec 31 2019US$2mUS$428k

-US$7m

報酬と市場: Bernardの 総報酬 ($USD 5.46M ) は、 US市場 ($USD 653.62K ) の同規模の企業の平均を上回っています。

報酬と収益: Bernardの報酬は、過去 1 年間の会社の業績と一致しています。

CEO

Bernard Coulie (60 yo)

10.6yrs
在職期間
US$5,462,901
報酬

Dr. Bernard Coulie M.D., Ph D., M.B.A. serves as an Independent Director at Redx Pharma Limited since August 2026. He is Independent Director of Biogazelle NV.Dr. Coulie is Independent Director of Septern...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Bernard Coulie
Presidentno dataUS$5.46m1.24%
$ 897.2k
Keith Cummings
Chief Financial Officer7.8yrsUS$2.40m0.39%
$ 283.2k
Minnie Kuo
Chief Operating Officerless than a yearUS$1.54m0.021%
$ 14.9k
Rik Derynck
Scientific Founder & Member of Scientific Advisory Board11.7yrsデータなしデータなし
Dean Sheppard
Scientific Founder & Member of Scientific Advisory Board11.7yrsデータなしデータなし
Hal Chapman
Scientific Founder & Member of Scientific Advisory Board11.7yrsデータなしデータなし
Delphine Imbert
Chief Technical Officer1.7yrsデータなしデータなし
Christopher Keenan
Vice President of Investor Relations & Corporate Communications5.8yrsデータなしデータなし
Monica Sandberg
Vice Presidentless than a yearデータなしデータなし
Lily Cheung
Chief Human Resources Officer3.7yrsデータなし0.031%
$ 22.1k
Tim Machajewski
Senior VP & Head of Research1.6yrsデータなしデータなし
Scott Peters
Senior Vice President of Financeless than a yearデータなしデータなし
3.7yrs
平均在職期間
51yo
平均年齢

経験豊富な経営陣: PLRXの経営陣は 経験豊富 であると考えられます ( 3.7年の平均在職年数)。

取締役

名称ポジション在職期間報酬所有権
Bernard Coulie
President10.6yrsUS$5.46m1.24%
$ 897.2k
Rik Derynck
Scientific Founder & Member of Scientific Advisory Boardno dataデータなしデータなし
Dean Sheppard
Scientific Founder & Member of Scientific Advisory Boardno dataデータなしデータなし
Hal Chapman
Scientific Founder & Member of Scientific Advisory Boardno dataデータなしデータなし
Gayle Crowell
Independent Director6.8yrsUS$95.10k0%
$ 0
John Curnutte
Independent Director9.1yrsUS$82.60k0.047%
$ 34.3k
Hoyoung Huh
Independent Chairman & Lead Director8.8yrsUS$112.60k0.16%
$ 116.7k
Steve Krognes
Independent Director2.3yrsUS$95.10k0%
$ 0
Thomas McCourt
Independent Director3.5yrsUS$90.10k0%
$ 0
Darren Cline
Independent Director3.5yrsUS$90.10k0%
$ 0
Robert Iannone
Independent Directorless than a yearデータなしデータなし
Flavia Borellini
Independent Directorless than a yearデータなしデータなし
3.5yrs
平均在職期間
62yo
平均年齢

経験豊富なボード: PLRXの 取締役会 は 経験豊富 であると考えられます ( 3.5年の平均在任期間)。

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/09/14 15:36
終値2026/09/14 00:00
収益2026/06/30
年間収益2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した ご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Pliant Therapeutics, Inc. 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。11

アナリスト機関
Edward NashCanaccord Genuity
David LebowitzCitigroup Inc
Lut Ming ChengJ.P. Morgan